Skip to contentI
IDEAYA Biosciences, Inc.
I
IDYAIDEAYA Biosciences, Inc. Q2 2026 · 10-Q
Revenue$8.86M$8.86Mno prior Q2 2025 on file Net Income-$112.45M-$112.45MN/M vs Q2 2025 EPS Diluted-$1.22-$1.22N/M vs Q2 2025 Operating Income-$122,291,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IDEAYA Biosciences, Inc. · CIK 1676725 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$89,077,000N/M Margins · derivedOperating margin-1380.7%
Net margin-1269.6%
ended Jun 30, 2026 · filed Aug 4, 2026 · 35 d after period end